| Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. | |
| | |
MedLine Citation:
|
PMID: 15904630 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin-converting enzyme inhibition is not an effective antianginal therapy. Experimental data suggest that broader vasopeptidase inhibition may decrease the magnitude of demand-induced myocardial ischemia. A randomized, double-blind, placebo controlled parallel study evaluated omapatrilat, an inhibitor of angiotensin-converting enzyme and neutral endopeptidase. The primary objective was to compare maximum duration of exercise at peak plasma concentrations. Exercise treadmill studies were performed in 348 patients who had chronic angina at baseline and after 4 weeks of therapy with 80 mg/day omapatrilat or placebo. Safety data were collected and reported for all patients. Treadmill exercise duration at peak was significantly prolonged in the omapatrilat group compared with the placebo group (76.6 +/- 84.2 vs 28.7 +/- 82.2 seconds difference from baseline, p <0.001). Similar statistically significant increases were seen in time to onset of level III/IV angina and time to onset of >/=0.1-mV ST-segment depression (p <0.001). The significant improvements in exercise duration and measurements of myocardial ischemia were not sustained 20 to 28 hours after dosing. Omapatrilat was generally well tolerated in this predominantly normotensive population. The incidence of serious adverse events was 5.2% in the 2 groups. Thus, omapatrilat, an investigational vasopeptidase inhibitor, is effective in prolonging exercise duration and parameters of demand-induced myocardial ischemia in patients who have chronic angina at peak concentrations. The data confirm the proof of principle that broader vasopeptidase inhibition beyond angiotensin-converting enzyme inhibition is required to alleviate symptoms of chronic angina. |
| | |
Authors:
|
Bernard R Chaitman; Alla Y Ivleva; Marek Ujda; Jacque H F Lenis; Csaba Toth; David M Stieber; Leonardo H Reisin; Andreas M Pangerl; Julie B Friedman; John H Lawrence |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The American journal of cardiology Volume: 95 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2005 Jun |
Date Detail:
|
Created Date: 2005-05-20 Completed Date: 2005-07-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1283-9 Citation Subset: AIM; IM |
Affiliation:
|
Saint Louis University School of Medicine, St. Louis, Missouri 63117, USA. chaitman@slu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angina Pectoris
/
drug therapy* Angiotensin II / analogs & derivatives*, blood Angiotensin III / blood Angiotensin-Converting Enzyme Inhibitors / administration & dosage, adverse effects, therapeutic use* Cardiovascular Agents / administration & dosage, adverse effects, therapeutic use* Chronic Disease Double-Blind Method Exercise Tolerance / drug effects* Female Humans Male Middle Aged Neprilysin / antagonists & inhibitors* Pyridines / administration & dosage, adverse effects, therapeutic use* Thiazepines / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiovascular Agents; 0/Pyridines; 0/Thiazepines; 0/omapatrilat; 11128-99-7/Angiotensin II; 12687-51-3/Angiotensin III; 23025-68-5/angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; EC 3.4.24.11/Neprilysin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from th...
Next Document: Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary synd...